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Abstract: Sectioning a whole tissue microarrray (TMA block)
and storing the sections maximizes the number of sections ob-
tained, but may impair the antigenicity of the stored sections.
We have investigated the impact of TMA section storage on
antigenicity. First, we reexamined existing TMA data to de-
termine whether antigenicity in stored sections changes over
time. Component scores for each marker, based on cellular
compartment of staining and score-type, were evaluated sepa-
rately. Residual components scores adjusted for grade, tumor
size, and node positivity, were regressed on the number of days
storage to evaluate the eﬀect of storage time. Storage time
ranged from 2 to 1897 days, and the mean change in antigenicity
per year ranged from 0.88 (95% conﬁdence interval, 1.11 to
0.65) to 0.035 (95% conﬁdence interval, 0.016-0.054). Further
analysis showed no signiﬁcant improvement in the ﬁt of survival
models if storage time adjusted scores were included in the
models rather than unadjusted scores. We then compared 3
ways of processing TMA sections after cutting—immediate
staining, staining after 1 year, and staining after 1 year coated in
wax—on the immunohistochemistry results for: progesterone
receptor, a routinely used, robust antibody, and MKI67, which
is generally considered less robust. The progesterone receptor
scores for stored sections were similar to those for unstored
sections, whereas the MKI67 scores for stored sections were
substantially different to those for unstored sections. Wax
coating made little difference to the results. Biomarker anti-
genicity shows a small decline over time that is unlikely to have
an important effect on studies of prognostic biomarkers.
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BACKGROUND
Tissue microarrays (TMAs) constructed using ar-
chival, formalin-ﬁxed, paraﬃn-embedded pathology ma-
terial, are a standard tool for investigating tumor
biomarkers in large-scale clinical epidemiological studies.
The reliability of TMAs in such studies has been inves-
tigated primarily by focussing on the number of cores
needed from each case to produce results equivalent to
those from whole tissue sections.1–3 However, for bio-
markers based on immunohistochemistry (IHC) the
quality of staining will depend on a wide range of factors.
These include preanalytical variables such as the handling
and ischemic time of the fresh tumor sample at the time of
surgery, the length of ﬁxation and method of tissue pro-
cessing used, the duration of storage of the paraﬃn
blocks, and the environment in which they are stored, and
the methods for TMA construction, the storage con-
ditions for the TMA, the methods for processing TMA
sections; and analytical variables within the protocol for
the IHC such as antigen retrieval and staining times. The
research laboratory often has little control over the initial
preanalytical steps, however they can optimize the pro-
cesses involved in TMA construction, sectioning, and
staining. To maximize the number of usable sections
available from a single TMA it is common to cut multiple
sections at a time to avoid loss of tissue from trimming
the block on multiple occasions, and to store the sections
for future IHC. However, the eﬃciency of this approach
needs to be balanced against the potential for loss of
antigenicity over time due to oxidation of the cut sections.
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Fergenbaum et al4 showed that antigenicity declined
over 6 months for breast TMA sections cut and stored at
room temperature. Beckstead5 evaluated a specialized
ﬁxative solution of zinc salts prepared in a Tris-Ca buﬀer
and found antigen preservation was comparable with
frozen sections in blocks stored for up to 3 years, but did
not investigate the storage of cut sections. However, the
utility of this method is limited because TMAs are usually
constructed from archival pathology material so the ﬁx-
ation of the original donor blocks is beyond the control of
the research team. Others have reported that coating cut
sections in paraﬃn wax followed by storage in a nitrogen
dessicator preserved antigenicity for up to 3 months.6
Although this may be a useful approach, specialized
equipment for storage of cut sections is not available in
many research facilities.
We have generated a large TMA resource that has
been used in several large-scale biomarker studies in both
breast and ovarian cancer.7–10 We routinely cut multiple
sections from a single TMA block and store these sections
for a variable time after cutting. The aim of this study was
to evaluate the impact of long-term section storage on the
antigenicity of multiple markers. The eﬀect on anti-
genicity of dipping a freshly cut and mounted section in
paraﬃn wax before long-term storage was also assessed.
METHODS
Patient Data
We used data generated from TMAs constructed using
archival tumor material from patients in the Study of
Epidemiology and Risk factors in Cancer Heredity
(SEARCH) breast cancer study, a population-based study of
breast cancer. Women diagnosed since 1996 with invasive
breast cancer before age 70 in the region served by the Na-
tional Cancer Registration Service Eastern Oﬃce (formerly
Eastern Cancer Registration and Information Centre) were
eligible to participate. To date, over 13,000 women with
breast cancer have enrolled in SEARCH. Information on
tumor size, node status, and grade was available from the
medical records. In addition, vital status, cause of death, and
follow-up time data were available from ECRIC. Archival
pathology material from 4125 of these patients has been
retrieved from multiple hospital pathology departments
across the region for TMA construction. SEARCH has
ethical approval from the Multicentre Research Ethics
Committee and all the participants have provided informed
written consent for their pathology material to be used.
TMA Construction, Staining, and Scoring
TMAs were constructed using donor pathology
blocks taken from patients under the age of 70 years with
invasive breast cancer. Core selection was guided by
hematoxylin and eosin–stained slides marked by a path-
ologist (H.R.A., J.L.Q., or E.P.) for invasive carcinoma.
One hundred seventy-two 0.6mm cores were arrayed in
each TMA plus 10 orientation cores; each tumor is rep-
resented by a single 0.6mm core in a TMA constructed
from paraffin-embedded tissue blocks. After construction
the TMAs were heated to 421C for 30 minutes and cooled
to room temperature 3 times. TMA sections 3 mm thick
were cut and mounted on glass slides. These sections were
stored for a variable length of time before IHC. Sections
were dewaxed in clearene and rehydrated through graded
alcohols. IHC was performed using a Bond-Max Autos-
tainer (Leica, UK) as detailed below.
Existing IHC data were available for ALDH1A1,
ALDH1A3,11 AURKA, GMNN, MKI67, MCM2,
PLK1,7,12 ER, progesterone receptor (PGR), EGFR,
CK5/6,13 ASMA, CK14,14 CDH1,15 GATA3,9 AR,
CTNNB1, FGFR2, FOXP3, KIT, MAP3K1, MYB,
NAT1, PDCD4, PTEN, SLC7A5, TP53 (unpublished
data) together with date of TMA sectioning and date of
IHC processing. Details of reagents and antigen retrieval
conditions are summarized in Supplementary Table 1, Sup-
plemental Digital Content, http://links.lww.com/AIMM/A64.
The Ariol platform (Genetic Limited, UK) was used to scan
the stained slides and the resulting images were used for
scoring. The markers were scored for one or more cellular
compartment (nucleus, cytoplasm, and membrane) and some
markers were scored for both intensity of staining and pro-
portion of cells staining positive. Details of the scoring system
for all markers are provided in Supplementary Table 2,
Supplemental Digital Content, http://links.lww.com/AIMM/
A64. Scoring was carried out by a pathologist (H.R.A.,
J.L.Q., E.P.) or by a specially trained oncologist (S.-J.D.). In
total there were 54 unique combinations of marker, cell
compartment, and score-type (component scores).
To evaluate the eﬀect of storage method on anti-
genicity we used four 3-mm sections cut from each of 2
TMAs and placed onto SuperFrost plus microscope slides.
Two of these were dipped in paraﬃn wax and 2 left exposed
to the air. They were then stored in the dark at ambient
temperature for 12 months. After 12 months 2 more sec-
tions were cut from each TMA and placed onto SuperFrost
plus microscope slides, giving a total of 6 sections from
each TMA; 2 dipped in paraﬃn wax and stored for 12
months, 2 exposed to the air and stored for 12 months, and
2 freshly cut (referred to as dipped, undipped, and fresh).
The 6 sections were all stained at the same time for PGR
and MKI67 using a Leica Bond-Max Autostainer. We used
a mouse monoclonal antibody for PGR (DAKO catalog
number M3569, lot number 00533, clone, PgR636, isotype
IgG1). This was diluted in Bond diluent to a concentration
of 1:50. For MKI67 a mouse monoclonal antibody was
used (DAKO catalog number M2740, lot number
00027229, clone MIB-1, isotype IgG1). This was diluted
using Bond diluent to a concentration of 1:200.
All the cores were scored once by the same patholo-
gist (H.R.A.) for intensity on a 4-point scale (0=no
staining, 1=weak, 2=moderate, and 3=strong), and for
proportion of positive nuclei on a 6-point scale (0=0%,
1=<1%, 2=1 to <10%, 3=10 to <34%, 4=34 to
<67%, 5=67 to <100%).
Statistical Methods
We evaluated the potential association between
IHC scores and storage time using linear regression.
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However, marker expression is known to vary by tumor
characteristics such as tumor size, tumor grade, and node
status. This may attenuate any association with storage
time. We therefore carried out a linear regression for each
component score against tumor grade, tumor size, and
number of nodes positive and estimated a residual for
each component score for each TMA core (equivalent to
the score adjusted for grade, size, and node status). As-
sociation between marker expression and number of days
between sectioning and staining was then carried out by
TABLE 1. Change in Antigenicity Over Time for Each Marker Component












ACTA1 C 1 1633 41 2 244 0.056 0.10 0.010 0.017
ALDH1A1 C 1 2275 636 33 1271 0.12 0.14 0.094 <0.0001
ALDH1A1 C 2 2275 636 33 1271 0.20 0.23 0.16 <0.0001
ALDH1A3 C 1 2165 960 12 1525 0.063 0.089 0.037 <0.0001
ALDH1A3 C 2 2165 960 12 1525 0.17 0.23 0.11 <0.0001
AR N 1 1577 335 8 417 0.52 0.62 0.42 <0.0001
AR N 2 1577 335 8 417 0.88 1.11 0.65 <0.0001
AURKA C, N 2 1930 474 45 682 0.14 0.21 0.071 <0.0001
BCL2 C 1 2330 74 2 888 0.32 0.38 0.26 <0.0001
BCL2 C 3 2330 74 2 888 0.37 2.47 1.74 0.73
CASP8 C 1, 3 306 77 45 142 0.78 1.35 0.20 0.0080
CDH1 M 1, 2 1735 171 9 404 0.33 0.40 0.26 <0.0001
CTNNB1 C 1 725 917 375 964 0.0017 0.091 0.087 0.97
CTNNB1 C 2 725 917 375 964 0.37 0.62 0.11 0.0040
CTNNB1 M 1 725 917 375 964 0.041 0.149 0.066 0.45
CTNNB1 M 2 725 917 375 964 0.28 0.52 0.048 0.018
CTNNB1 N 1 725 917 375 964 0.083 0.13 0.032 0.0010
CTNNB1 N 2 725 917 375 964 0.15 0.22 0.071 <0.0001
EGFR M 1 1906 192 11 567 0.01 0.093 0.077 0.85
EGFR M 2 1906 192 11 567 0.048 0.20 0.11 0.55
ERBB2 M 7 2402 42 7 278 0.11 0.25 0.035 0.14
ESR1 N 1 2307 20 2 233 0.34 0.51 0.17 <0.0001
ESR1 N 2 2307 20 2 233 0.37 0.680 0.060 0.019
FGFR2 C, M 1 1544 588 184 670 0.18 0.280 0.072 0.0010
FGFR2 C, M 2 1544 588 184 670 0.74 0.941 0.539 <0.0001
FOXP3 N 1 1840 1305 314 1897 0.035 0.016 0.054 <0.0001
FOXP3 N 2 1840 1305 314 1897 0.035 0.007 0.063 0.015
GATA3 N 1 1590 384 9 665 0.61 0.71 0.51 <0.0001
GATA3 N 2 1590 384 9 665 0.80 1.00 0.60 <0.0001
GMNN N 2 1943 735 126 1133 0.050 0.10 0.005 0.075
KIT M 4 1667 354 8 587 0.031 0.069 0.006 0.10
KRT14 C 4 1718 20 2 233 0.004 0.046 0.038 0.86
KRT5/6 C 4 2370 20 2 433 0.011 0.055 0.034 0.63
MAP3K1 C 1 1487 503 99 585 0.46 0.57 0.35 <0.0001
MAP3K1 C 2 1487 503 99 585 0.81 1.06 0.57 <0.0001
MCM2 N 1 1598 607 184 883 0.46 0.56 0.37 <0.0001
MCM2 N 2 2202 476 7 883 0.79 0.88 0.70 <0.0001
MKI67 N 2 2447 162 7 617 0.17 0.29 0.038 0.011
MYB N 1 1471 665 123 760 0.45 0.52 0.37 <0.0001
MYB N 2 1471 665 123 760 0.57 0.70 0.44 <0.0001
NAT1 C 1 1555 553 149 635 0.41 0.51 0.31 <0.0001
NAT1 C 2 1555 553 149 635 0.74 0.95 0.53 <0.0001
PDCD4 C 1 1588 616 71 887 0.30 0.35 0.26 <0.0001
PDCD4 N 1 1588 616 71 887 0.44 0.50 0.38 <0.0001
PGR N 1 2311 20 2 433 0.051 0.19 0.087 0.47
PGR N 2 2311 20 2 433 0.073 0.31 0.16 0.54
PLK1 C, N 2 1423 616 7 1014 0.12 0.18 0.059 <0.0001
PTEN C 1 1745 777 176 1353 0.21 0.26 0.17 <0.0001
PTEN C 2 1745 777 176 1353 0.47 0.58 0.37 <0.0001
PTEN N 1 1745 777 176 1353 0.22 0.26 0.17 <0.0001
PTEN N 2 1745 777 176 1353 0.55 0.65 0.44 <0.0001
SLC7A5 C 1 1415 521 130 754 0.25 0.34 0.16 <0.0001
SLC7A5 C 2 1415 521 130 754 0.78 1.06 0.51 <0.0001
TP53 N 1 2467 321 9 888 0.087 0.13 0.046 <0.0001
1 indicates Allred type intensity; 2, Allred type proportion; 3, percentage; 4, Z10% of cells staining scored as positive; 7, standard clinical HER2 scoring; C,
cytoplasmic; LCL, lower conﬁdence limit; N, nuclear; M, membranous; UCL, upper conﬁdence limit.
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linear regression of the component score residuals against
section storage time. The scores for dipped, undipped,
and fresh cores were compared using a kappa statistic.
To evaluate the importance of any loss of antigenicity
over time we evaluated the prognostic signiﬁcance of each
component score in 2 multivariable Cox proportional
hazards models of breast cancer–specific survival. In 1
model the observed score was used and in the second model
the score adjusted for storage time was used. Grade, size,
and node status were included as covariates in both models.
The models were compared using the model log likelihood
statistics.
RESULTS
The number of cases with IHC and clinical data
ranged from 306 for CASP8 to 2467 for TP53. Scatterplots
of the score residuals against storage time are shown in
Supplementary Figure 1, Supplemental Digital Content,
http://links.lww.com/AIMM/A64. The mean change in
antigenicity over time for each marker component is shown
in Table 1. All but 2 of the marker components showed a
decline in antigenicity over time and for 40 of them the
decline was signiﬁcant at a nominal P<0.05. However, the
loss of antigenicity was small. The biggest eﬀect was seen
for the proportion score for nuclear androgen receptor,
which declines on an average by 0.88 units per
year. Figure 1 shows the mean change in antigenicity for
cytoplasmic and nuclear markers stratiﬁed by intensity and
proportion scores. The decline in antigenicity for cyto-
plasmic proportion, nuclear intensity, and nuclear pro-
portion scores was similar, but the decline in cytoplasmic
intensity scores was greater. The results of the Cox re-
gression models carried out on each marker component
indicated that there was no improvement in the ﬁt of the
model when storage time was included (data not shown).
We compared the IHC scores for PGR and MKI67
for dipped, undipped, and fresh sections. Typical exam-
ples of the IHC of the same core processed by these
methods are shown in Supplementary Figure 2, Supple-
mental Digital Content, http://links.lww.com/AIMM/
A64. Weighted scatterplots for each comparison pair of
scores of these results are shown in Figure 2 (n=133 to
153 paired scores). For fresh compared with dipped sec-
tions, weighted kappa values of 0.89, 0.80, 0.64, and 0.44
were obtained for PGR proportion, PGR intensity,
MKI67 proportion, and MKI67 intensity, respectively.
The equivalent values were 0.91, 0.80, 0.72, and 0.54 for
fresh compared with undipped sections and for dipped
compared with undipped the scores were 0.93, 0.86, 0.77,
and 0.45. If the commonly used scale of: 0.01 to
0.20=slight agreement, 0.21 to 0.40 fair agreement, 0.41
to 0.60 moderate agreement, 0.61 to 0.80 substantial
agreement, 0.81 to 0.99 almost perfect agreement, is ap-
plied all the kappa values obtained indicated at least
moderate agreement.
DISCUSSION
The results obtained by these analyses show that
there is a signiﬁcant but small decline in antigenicity with
increasing storage time; however, when scores adjusted
for storage time are used in multivariable survival time
Cox regression models there is no improvement in the ﬁt
of the model compared with a similar model with un-
FIGURE 1. Change in component marker scores per year of
storage time.
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FIGURE 2. Weighted scatterplot of component marker scores by processing method. A, MKI67 intensity dipped versus not-
dipped. B, MKI67 intensity dipped versus fresh. C, MKI67 intensity not-dipped versus fresh. D, PGR intensity dipped versus
not-dipped. E, PGR intensity dipped versus fresh. F, PGR intensity not-dipped versus fresh. G, MKI67 proportion dipped versus
not-dipped. H, MKI67 proportion dipped versus fresh. I, MKI67 proportion not-dipped versus fresh. J, PGR proportion dipped
versus not-dipped. K, PGR proportion dipped versus fresh. L, PGR proportion not-dipped versus fresh. PGR indicates progesterone
receptor.
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adjusted scores. This may be because antigenicity simply
declines proportionately across all IHC subtypes.
The results of the experiment using 2 diﬀerent
storage methods of TMA sections after cutting and
freshly cut sections, provide evidence that when using a
robust IHC marker such as PGR, scores obtained from
sections cut and stored for a year were similar to those
obtained from freshly cut sections. However, for MKI67,
the less robust marker, the correlation between scores for
freshly cut and stored sections was weaker. The method
of storage made little diﬀerence to this. The diﬀerence in
the eﬀect of storage on PGR and MIKI67 was also found
in the analysis of the eﬀect of storage time on the
SEARCH TMAs with a reduction in the proportion score
for PGR of 0.073 per year compared with a reduction of
0.17 for the MKI67 proportion score (Table 1).
There are many possible methods that might be
used to reduce the time dependent decline in antigenicity,
but the utility of evaluating these is likely to be limited
given the small decline in antigenicity for sections stored
for up to a year. A 1 year storage time is longer than that
evaluated in previous research. Nevertheless, many
pathology and/or research facilities store cut sections for
much longer. Given that the observations in this study
may not be linear with increasing lengths of time testing
of the impact of storage time is an important parameter
that investigators involved in biomarker studies should
address in their study design.
Our data suggest that medium-term storage time for
sections cut from TMAs is not a major factor in the re-
liability of most IHC biomarkers. In large-scale studies
evaluating multiple biomarkers, the cutting of multiple
sections from a TMA for future staining is an eﬃcient use
of a scarce resource that will not aﬀect adversely the
ﬁndings of biomarker studies.
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